Recent News

• 08.21.2025 - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
• 08.21.2025 - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investor Conference
• 08.14.2025 - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.14.2025 - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
• 06.30.2025 - Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
• 06.11.2025 - Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
• 06.11.2025 - Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
• 06.03.2025 - Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
• 06.03.2025 - Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

Recent Filings

• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.11.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.01.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.23.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]